Harmony Biosciences Holdings (HRMY) Share-based Compensation (2019 - 2026)

Harmony Biosciences Holdings' Share-based Compensation history runs 8 years deep, the most recent figure standing at $10.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 15.03% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $43.0 million (down 4.37% YoY), while the FY2025 annual figure was $44.9 million, up 5.38% from the prior year.
• Share-based Compensation came in at $10.6 million for Q1 2026 at Harmony Biosciences Holdings, up from $10.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $12.5 million in Q1 2025 to a low of $4.6 million in Q1 2022.
• A 5-year average of $9.2 million and a median of $10.0 million in 2025 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 93.62% in 2022 and retreated 15.03% in 2026, its largest moves.
• Harmony Biosciences Holdings' Share-based Compensation stood at $6.9 million in 2022, then soared by 35.38% to $9.4 million in 2023, then gained by 7.22% to $10.1 million in 2024, then declined by 0.99% to $10.0 million in 2025, then gained by 6.5% to $10.6 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $10.6 million, $10.0 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison